Upstate Active Clinical Trials
Study Title:A Randomized Phase II study of Brentuximab Vedotin (NSC# 749710) and Crizotinib (NSC# 749005) in Patients with Newly Diagnosed Anaplastic Large Cell Lymphoma
What is the purpose of the study?Study to look at experimental drug combinations by adding brentuximab vedotin or crizotinib to standard chemotherapy in the hopes of finding a more effective treatment for ALCL.
Upstate Institutional Review Board (IRB) Number:542077
Patient Age Group:Children
Principal Investigator:Karol H Kerr, MD
Who can I contact for more information?
Name: Beatriz Kovar